FILINGS
| GSK 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2023-03-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-02-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-23 | 6-K | VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA | View Document |
| 2023-02-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-16 | 6-K | NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL | View Document |
| 2023-02-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-14 | SC 13G/A | SC 13G/A | View Document |
| 2023-02-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-10 | 6-K | JEMPERLI FULL FDA APPROVAL FOLLOWING GARNET TRIAL | View Document |
| 2023-02-10 | 6-K | JEMPERLI FDA ODAC POSITIVE OUTCOME | View Document |
| 2023-02-06 | SC 13G | SCHEDULE 13G | View Document |
| 2023-02-02 | 6-K | DAPRODUSTAT APPROVED BY US FDA FOR ANAEMIA OF CKD | View Document |
| 2023-02-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-02-01 | 6-K | BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA | View Document |
| 2023-02-01 | 6-K | FINAL RESULTS | View Document |
| 2023-01-30 | SC 13G | SCHEDULE 13G | View Document |
| 2023-01-30 | 3 | INITIAL STATEMENT OF BENEFICIAL OWNERSHIP | View Document |
| 2023-01-20 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document |
| 2023-01-20 | SC 13D/A | SCHEDULE 13D/A | View Document |
| 2023-01-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-01-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-01-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-01-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-01-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-01-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-12-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-12-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-12-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-12-15 | 6-K | BOARD AND COMMITTEE CHANGES | View Document |
| 2022-12-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-12-07 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2022-12-05 | 6-K | TRANSFER OF TREASURY SHARES | View Document |
| 2022-12-02 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-12-02 | 6-K | JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER | View Document |
| 2022-12-02 | 6-K | EMA FILE ACCEPTED FOR MOMELOTINIB | View Document |
| 2022-12-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-11-25 | 6-K | GSK PUBLISHES PROVISIONAL 2023 DIVIDEND DATES | View Document |
| 2022-11-22 | 6-K | BLENREP US UPDATE | View Document |
| 2022-11-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-11-15 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2022-11-14 | 3 | View Document | |
| 2022-11-14 | SC 13D/A | SCHEDULE 13D/A | View Document |
| 2022-11-14 | 6-K | GSK UPDATE: ZEJULA 2L IN US | View Document |
| 2022-11-10 | 6-K | SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EU | View Document |
| 2022-11-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-11-10 | 6-K | BLOCK LISTING APPLICATION | View Document |
| 2022-11-07 | 6-K | DREAMM-3 PHASE III TRIAL FOR BLENREP | View Document |
| 2022-11-04 | 3 | ME - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP | View Document |
| 2022-11-04 | SC 13D | ACQUISITION OF BENEFICIAL OWNERSHIP | View Document |
| 2022-11-03 | 6-K | IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP | View Document |
| 2022-11-02 | 6-K | 3RD QUARTER RESULTS | View Document |
| 2022-11-02 | 6-K | GSK RSV VACCINE: US FDA PRIORITY REVIEW | View Document |
| 2022-11-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-10-28 | 6-K | EMA ACCEPTS GSK RSV OLDER ADULT VACCINE FOR REVIEW | View Document |
| 2022-10-28 | 6-K | EMA VALIDATES MAA FOR CABOTEGRAVIR LA FOR PREP | View Document |
| 2022-10-27 | 6-K | GSK ANNOUNCES FDA MEETING OUTCOME ON DAPRODUSTAT | View Document |
| 2022-10-27 | 6-K | CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATE | View Document |
| 2022-10-25 | 6-K | BOARD COMMITTEE CHANGES | View Document |
| 2022-10-21 | 6-K | RSV OLDER ADULT VACCINE SUBMISSION IN JAPAN | View Document |
| 2022-10-17 | 6-K | MENVEO NEW SINGLE-VIAL APPROVED BY US FDA | View Document |
| 2022-10-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-10-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-10-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-10-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-10-13 | 6-K | EFFICACY RESULTS FOR GSK'S OLDER ADULT RSV VACCINE | View Document |
| 2022-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-10-11 | 6-K | US FDA APPROVES BOOSTRIX MATERNAL IMMUNISATION | View Document |
| 2022-10-07 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-10-07 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-10-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-09-30 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-09-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-09-26 | 6-K | GSK CHIEF FINANCIAL OFFICER SUCCESSION | View Document |
| 2022-09-22 | 6-K | US FDA ODAC REVIEW OF ZEJULA PHASE III NOVA TRIAL | View Document |
| 2022-09-22 | 6-K | GSK AND SPERO THERAPEUTICS LICENCE FOR TEBIPENEM | View Document |
| 2022-09-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-09-20 | 4 | View Document | |
| 2022-09-20 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document |
| 2022-09-15 | 25-NSE | View Document | |
| 2022-09-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-09-08 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-09-06 | 6-K | GSK PROVIDES UPDATE ON FDA REVIEW OF DAPRODUSTAT | View Document |
| 2022-09-01 | 25-NSE | View Document | |
| 2022-09-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-08-24 | 6-K | GSK BOARD CHANGES | View Document |
| 2022-08-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-08-17 | 6-K | FDA NEW DRUG APPLICATION FILE ACCEPTANCE FOR MMB | View Document |
| 2022-08-17 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION UPDATE | View Document |
| 2022-08-16 | 6-K | GSK COMPLETES ACQUISITION OF AFFINIVAX, INC. | View Document |
| 2022-08-12 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2022-08-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-08-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-08-03 | 6-K | CURRENT REPORT OF FOREIGN ISSUER | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
